| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026 |
| 05 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research |
| 02 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
As representative (the “Representative”) of the several Underwriters |
| 31 Aug 2026 |
8-K: Other Events
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed |
| 05 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2026, PMV Pharmaceuticals, Inc. (the “Company”) held its virtual 2026 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual M... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancer |
| 06 Mar 2026 |
8-K: Results of Operations and Financial Condition
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Updated clinical results from Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt featured in late-breaking oral presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
| 10 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
PYNNACLE Phase 2 Clinical Data Update Investor Webinar September 10, 2025 Exhibit 99.1 |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis data |
| 09 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 5, 2025, PMV Pharmaceuticals, Inc. (the “Company”) held its virtual 2025 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual M... |
| 09 May 2025 |
8-K: Results of Operations and Financial Condition
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors |
| 03 Mar 2025 |
8-K: Results of Operations and Financial Condition
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe... |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and As... |
| 08 Aug 2024 |
8-K: Termination of a Material Definitive Agreement; Results of Operations and Financial Condition
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial |
| 07 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 6, 2024, PMV Pharmaceuticals, Inc. (the “Company”) held its virtual 2024 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual M... |
| 09 May 2024 |
8-K: Results of Operations and Financial Condition
First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors |
| 29 Feb 2024 |
8-K: Results of Operations and Financial Condition
Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wil... |
| 18 Jan 2024 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30% |
Loading...